Skip to Main Content
our new site.
NLM Technical Bulletin
Full Text View
Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)
This study has been completed.
Study NCT00724958 Information provided by Merck Sharp & Dohme Corp.
First Received on July 25, 2008. Last Updated on October 1, 2015
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Digestive System Diseases
Inflammatory Bowel Diseases
Interventions listed in this trial
More general drug interventions related to this trial
Anti-Inflammatory Agents, Non-Steroidal
Central Nervous System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Sensory System Agents
Sponsors listed in this trial
Merck Sharp & Dohme Corp.
Back to top of Main Content
Contact Help Desk
Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
U.S. National Institutes of Health
U.S. Department of Health & Human Services
Freedom of Information Act
Links to all studies - primarily for crawlers